ENVB doubles after USPTO signals approval of key patent filing

Enveric Biosciences shares jumped more than 106% in premarket trade, after the company received a USPTO Notice of Allowance for its patent covering its EVM301 molecule series. The notice indicates the patent is likely to be granted, and strengthens Enveric competitive position in neuropsychiatric treatments.